PACAP-27 vs Statherin
Head-to-head comparison of PACAP-27 (Pituitary Adenylate Cyclase-Activating Polypeptide-27) and Statherin (Human statherin) — benefits, dosing, side effects, research data, and where to buy.
| Property | PACAP-27 | Statherin |
|---|---|---|
| Category | Diabetes & Metabolic | Dental & Oral |
| Full Name | Pituitary Adenylate Cyclase-Activating Polypeptide-27 | Human statherin |
| Molecular Weight | 3158 Da | 5380 Da |
| Half-Life | minutes | minutes to hours in saliva |
| Amino Acids | 27 | 43 |
| Typical Dose | Research-only: 0.1-1 nmol/kg | 1-50 µM in experimental systems |
| Route | Intraperitoneal/Subcutaneous | Topical/Intraoral |
| Purity | ≥98% | ≥98% |
| Studies Count | 220 | 95 |
| Research Status | Pre-clinical | Pre-clinical |
PACAP-27 Benefits
- ✓anti-apoptotic signaling
- ✓insulin secretagogue effect
- ✓reduced ER stress
- ✓islet cytoprotection
Statherin Benefits
- ✓enamel pellicle stabilization
- ✓calcium phosphate homeostasis
- ✓remineralization support
- ✓anti-adhesion
PACAP-27 Dosing
0.1-1 nmol/kg in animal studies|10-100 nM in vitro|research-only intermittent dosing
Statherin Dosing
topical peptide exposure in vitro or ex vivo|salivary-mimetic coating studies|surface-conditioning protocols
PACAP-27 Side Effects
- ⚠flushing
- ⚠hypotension at high exposure
- ⚠headache
Statherin Side Effects
- ⚠minimal systemic effects expected
- ⚠surface adsorption variability
- ⚠rapid enzymatic breakdown
Research Overview
PACAP-27
PACAP-27 has been repeatedly shown to support beta-cell survival through cAMP/PKA and related pathways. In experimental models it mitigates cytokine damage, preserves insulin content, and helps maintain islet viability.
Statherin
Statherin has been extensively studied as a key regulator of enamel mineral equilibrium and pellicle biology. It is used in biomimetic dentistry research to model or improve enamel protection and remineralization.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.